PsychoGenics to provide testing services in the R6/2 Mouse Model for Huntington Disease

July 6, 2005 - PsychoGenics Inc. Tarrytown, New York has signed a license agreement enabling it to provide behavioral phenotyping and compound evaluation services using the transgenic R6/2 mouse model for Huntington Disease. Huntington Disease is a devastating and ultimately fatal neurological condition for which no treatment currently exists. The Huntington animal model provides a valuable discovery tool to aid in the development of much needed drugs.Under the terms of the license agreement, PsychoGenics is now able to provide third-party testing in the R6/2 model. The terms of the agreement are undisclosed, however, there are no reach-through obligations on PsychoGenics' clients.Read More.

PsychoGenics Names Paul McGonigle Chief Scientific Officer, and Jeff Schneider Chief Informatics Officer

November 15, 2004 – PsychoGenics, Inc., a leader in preclinical neurobiology and CNS drug discovery solutions, today announced an expansion of its executive management team. Effective immediately Paul McGonigle, Ph.D., co-founder and former CEO of NeuroGenix Corporation, has been named Chief Scientific Officer, and Jeff Schneider, Ph.D., Associate Research Professor at Carnegie Mellon University’s Robotics Institute, has been appointed Chief Informatics Officer.Read More.

PsychoGenics Obtains Funding For Their High Throughput CNS Drug Discovery Platform

Hawthorne, New York, August 28, 2002, PsychoGenics Inc. announced today that its application to the National Institute of Mental Health of the National Institutes of Health for a fast-track (Phase I and II) Small Business Innovation Research (SBIR) grant, totaling $1,062,158, has been approved. The grant will help support the further development of SmartCubeTM, the first proprietary high-throughput system for testing behavior and physiology in live animals (in vivo). SmartCubeTM combines the company's expertise in behavioral pharmacology with innovations in robotics, computer vision and bioinformatics, bringing massively parallel data acquisition and analysis to the study of behavior and a new approach to central nervous system (CNS) drug discovery.Read More.

Mark Hofer Esq. Joins PsychoGenics as General Counsel

Hawthorne, New York, June 11, 2002, PsychoGenics Inc, a private biopharmaceutical company, with expertise in the field of behavioral neurobiology, and provider CNS drug discovery solutions to Pharmaceutical and Biotechnology companies, announces that Mark Hofer, Esq. has joined the Company as General Counsel taking a partial leave of absence to do so from Brown Rudnick Berlack & Israels, a general practice law firm headquartered in Boston with offices in New England, New York and London, where he headed the Firms biotech intellectual property group.Read More.